Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin; 18 september Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin; Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised Lees verder » Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief.